Compare WMK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | ARDX |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1994 | 2014 |
| Metric | WMK | ARDX |
|---|---|---|
| Price | $62.25 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 127.7K | ★ 3.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 5.96 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $4,714,573,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $38.22 |
| Revenue Next Year | N/A | $33.85 |
| P/E Ratio | $24.70 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $61.27 | $3.50 |
| 52 Week High | $90.23 | $8.40 |
| Indicator | WMK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 39.16 |
| Support Level | N/A | $5.49 |
| Resistance Level | $68.14 | $6.23 |
| Average True Range (ATR) | 2.29 | 0.36 |
| MACD | -1.04 | -0.04 |
| Stochastic Oscillator | 6.14 | 36.59 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.